MiNK Therapeutics, Inc. Overview
Pro stress-test →MiNK Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Strategic Profile
Pro stress-test →Clinical trial milestones for its lead iNKT therapy agenT-797 include Phase 1 and Phase 2 studies in checkpoint-refractory solid tumors, GvHD prevention in allogeneic stem cell transplantation, and critical pulmonary immune failure. Key clinical highlights include durable responses with agenT-797 in checkpoint- and chemotherapy-refractory solid tumors, including complete remissions >2 years and multi-year survivors, with no ≥Grade 3 CRS or neurotoxicity reported.
Competitive Landscape
Pro stress-test →iNKT cells combine durable memory responses with rapid cytolytic features of natural killer cells, offering distinct therapeutic advantages for allogeneic therapy with natural homing to tissues and ability to suppress Graft versus Host Disease. Main competitors in cell therapy for solid tumors include conventional CAR-T platforms (Juno, Gilead) and checkpoint inhibitor developers (Merck, BMS), though iNKT represents a distinct mechanism.
Industry Context
MiNK Therapeutics, Inc. operates in Clinical-stage biopharmaceutical / Cell Therapy / Immuno-oncology.
Key facts
Founded: 2017 · Headquarters: New York, United States